Business Context and Reporting Period
This summary covers the Annual Report on Form 20-F for Biovail Corporation (now Bausch Health Companies Inc.) for the fiscal year ended December 31, 2001. Biovail is a fully integrated international pharmaceutical company focused on developing, manufacturing, and marketing branded pharmaceutical products using proprietary controlled-release and FlashDose® technologies. The company operates primarily in the United States and Canada, with significant licensing activities globally.
Key Financial Metrics (U.S. GAAP)
| Metric | 2001 | 2000 | 1999 |
|---|---|---|---|
| Revenue | $583.3 million | $309.2 million | $172.5 million |
| Operating Income | $171.2 million | ($78.0 million) | ($40.2 million) |
| Net Income | $87.4 million | ($148.0 million) | ($110.0 million) |
| Diluted EPS | $0.58 | ($1.16) | ($1.07) |
| Cash and Equivalents | $434.9 million | $125.1 million | $178.1 million |
| Working Capital | $427.9 million | ($25.3 million) | $266.1 million |
| Long-term Obligations | $46.2 million | $438.7 million | $137.5 million |
| Shareholders' Equity | $1,126.1 million | $237.5 million | $267.3 million |
Note: 2000 and 1999 results included significant non-cash charges for acquired research and development and accounting principle changes.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 89% to $583.3 million, driven primarily by the full-year contribution of the Cardizem® product line (acquired from Aventis in late 2000) and the DJ Pharma portfolio (acquired in October 2000). Product sales grew 139% year-over-year.
- Profitability Turnaround: The company returned to profitability with $87.4 million in net income, reversing a $148.0 million loss in 2000. This was aided by the absence of the $208.4 million acquired R&D charge recorded in 2000.
- Asset Write-downs: A non-cash charge of $80.5 million was recorded in 2001 related to the impairment of the Keftab and Dura-Vent product rights due to manufacturing issues and recalls.
- Debt Reduction: Long-term obligations decreased significantly from $438.7 million to $46.2 million. The company converted $300 million of Convertible Subordinated Preferred Equivalent Debentures into common shares and repaid the Cardizem® acquisition obligation.
- Liquidity: Cash and cash equivalents increased by $309.7 million to $434.9 million, supported by strong operating cash flow of $284.1 million and a $587.5 million equity offering in November 2001.
Guidance, Outlook, and Risks
Outlook and Strategy: Management views the company as financially well-positioned to execute growth strategies. Key strategic initiatives include the launch of Cardizem® XL (expected H2 2002), the co-promotion of Wellbutrin SR with GlaxoSmithKline (GSK), and the development of FlashDose® products. The company plans to expand its U.S. sales force to approximately 800 representatives by the end of 2002.
Recent Developments (Post-Year End):
- Acquired exclusive U.S. distribution rights to Zovirax® from GSK for $133 million (Jan 2002).
- Acquired U.S. marketing rights to Teveten® from Solvay for $94 million (Mar 2002).
- Issued $400 million in Senior Subordinated Notes (Mar 2002).
- Implemented a share repurchase program (Feb 2002).
Risks and Contingencies:
- Regulatory Approvals: Success depends on FDA and Canadian TPP approvals for pipeline products (e.g., Cardizem XL, FlashDose formulations). Delays could adversely affect results.
- Patent Litigation: The company faces ongoing patent infringement suits from Bayer/Pfizer regarding generic Procardia XL and Adalat CC, and from Andrx regarding Tiazac. Outcomes are uncertain and could delay market entry.
- Product Recalls: The Keftab recall by Eli Lilly caused significant revenue loss and asset impairment. Legal action is pending against Eli Lilly for damages.
- Competition: Intense competition from generic manufacturers and major pharmaceutical companies with greater resources.
Investor Verification Checklist
- Asset Impairment Validity: Verify the recoverability of the remaining intangible assets, specifically the $10 million residual value assigned to Keftab and the valuation of the Dura-Vent rights.
- Cardizem® XL Launch: Monitor the timeline for FDA approval and commercial launch of Cardizem XL, a key growth driver expected in late 2002.
- Legal Proceedings: Track the status of patent litigation with Bayer/Pfizer and Andrx, as well as the damages claim against Eli Lilly regarding the Keftab recall.
- Debt Covenants: Confirm continued compliance with the $400 million revolving credit facility covenants, particularly interest coverage and debt-to-EBITDA ratios.
- Integration of Acquisitions: Assess the successful integration and revenue contribution of recent acquisitions (Zovirax, Teveten) and the GSK partnership.